Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.88B 16.68B 15.15B 28.52B 1,940B 28.8B 200B 78.34B 986B 75.19B 73.56B 3,170B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 19.29B 17.99B 16.34B 30.75B 2,092B 31.05B 216B 84.48B 1,063B 81.09B 79.32B 3,418B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 57.75
Extreme 57.75
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
104.98
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap. Importance
23/03/26 Issuer sale

Director

28,899 0.0151%
23/03/26 Free

Executive/Senior Manager

199,374 0.1044%
23/03/26 Issuer sale

Director

20,558 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+81.66%+67.32% 20.03B
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.16%+2.68%+51.09% 58.7B
-2.39%+0.50%+3.41%+31.33% 48.36B
-6.57%-9.19%+291.00%+634.10% 43.05B
-0.24%-1.48%+28.04%+28.72% 42.48B
-4.36%-2.96%-0.84%+101.49% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.24%-4.45%-12.93%-15.34% 23.93B
-2.11%-8.37%-38.51%+305.96% 22.22B
Average -3.91%-2.37%+40.66%+134.30% 40.61B
Weighted average by Cap. -4.75%-1.79%+44.43%+130.89%

Financials

2024 2025
Net sales 2.76B 2.46B 2.3B 2.09B 3.93B 267B 3.97B 27.59B 10.79B 136B 10.36B 10.13B 437B 3.25B 2.9B 2.7B 2.46B 4.62B 314B 4.67B 32.48B 12.7B 160B 12.19B 11.93B 514B
Net income -1.03B -919M -857M -779M -1.47B -99.65B -1.48B -10.29B -4.02B -50.63B -3.86B -3.78B -163B -208M -186M -173M -157M -296M -20.14B -299M -2.08B -813M -10.23B -781M -764M -32.91B
Net Debt 1.74B 1.55B 1.45B 1.32B 2.47B 168B 2.5B 17.38B 6.8B 85.52B 6.52B 6.38B 275B 1.57B 1.4B 1.31B 1.19B 2.24B 152B 2.26B 15.7B 6.14B 77.27B 5.9B 5.77B 249B
Projected Income Statement - Annual - Exact Sciences Corporation
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Ratings Surperformance© - Exact Sciences Corporation
  1. Stock Market
  2. Stocks
  3. EXAS Stock